Could a common drug make radiation deadlier to lung tumors?
NCT ID NCT03824327
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding a drug called papaverine to precise, high-dose radiation (SBRT) can help control non-small cell lung cancer. About 19 patients with a single lung tumor will receive both treatments. The main goal is to find the safest dose and see if the combination improves tumor control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Papaverine hydrochloride (a drug that may make cancer cells more sensitive to radiation)
- What this could lead to
- If it works, this could point toward a way to make radiation therapy more effective for lung cancer, potentially improving tumor control.
- What could go wrong
- This is a very early (Phase I) trial with only 19 participants, so it is primarily testing safety and dosing. It may not show a clear benefit, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could lung cancer patients get immunotherapy less often?
- New combo aims to stall lung Cancer's spread
- New tool may help older cancer patients avoid harsh chemo side effects
- DNA vaccine aims to train immune system against lung cancer
- Lung cancer vaccine shows promise in early prevention trial